Validation of the updated eighth edition of AJCC for prostate cancer: Removal of pT2 substages - Does extent of tumor involvement matter?
Beteiligte Einrichtungen
Abstract
BACKGROUND: Updates in the eighth edition of the AJCC prostate cancer staging manual include removal of the organ-confined (pT2) substages.
METHODS: Retrospective analyses of 12,028 pT2 patients that underwent radical prostatectomy between 2003 and 2016 and did not receive neo- or adjuvant treatments. Kaplan-Meier curves as well as multivariable Cox-regression analyses compared biochemical recurrence (BCR), metastatic progression (MP) and overall mortality (OM) between the 3 subcategories (pT2a, pT2b and pT2c).
RESULTS: After surgery, 1,441 patients were classified as pT2a, 126 as pT2b and 10.495 as pT2c. Five-year BFS rates for pT2a, pT2b and pT2c were 92.0% vs. 97.4% vs. 88.0%. For the same groups, 5-year MP-FS rates were 99.5% vs. 100% vs. 99.0% and 5-year OS rates were 98.0% vs. 98.2% vs. 97.7%. In multivariable analyses pT2 substratification did not reach independent predictor status for biochemical recurrence, MP or overall mortality.
CONCLUSIONS: Substratification of pT2 prostate cancer was not predictive for further disease progression. Therefore, removing the substages simplifies the staging system without loss of important information.
Bibliografische Daten
Originalsprache | Englisch |
---|---|
ISSN | 1078-1439 |
DOIs | |
Status | Veröffentlicht - 07.2020 |
Anmerkungen des Dekanats
Copyright © 2020. Published by Elsevier Inc.
PubMed | 32245678 |
---|